Urinary Albumin-to-Creatinine Ratio Tertiles Predict Risk of Diabetic Retinopathy Progression: A Natural History Study from The Adolescent Cardio-Renal Intervention Trial (AdDIT) observational cohort
Dalton, R Neil
MetadataShow full item record
Marcovecchio, L., Benitez-Aguirre, P., Chiesa, S., Craig, M., Wong, T., Davis, E., Cotterill, A., et al. Urinary Albumin-to-Creatinine Ratio Tertiles Predict Risk of Diabetic Retinopathy Progression: A Natural History Study from The Adolescent Cardio-Renal Intervention Trial (AdDIT) observational cohort. Diabetologia https://doi.org/10.17863/CAM.78690
Aims/hypothesis We hypothesised that adolescents with type 1 diabetes with a urinary albumin-to-creatinine ratio (ACR) in the upper tertile of the normal range (high-ACR) are at greater risk of 3-step diabetic retinopathy progression (3DR) independent of glycaemic control. Methods Prospective observational study in 710 normoalbuminuric adolescents with type 1 diabetes from the non-intervention cohorts of AdDIT (ISRCTN91419926). Participants were classified as ‘high-ACR’ or ‘low-ACR’ (lowest and middle ACR tertiles) using baseline standardised logACR. The primary outcome (3DR) was determined from centrally graded, standardised two-field retinal photographs. 3DR risk was determined using multivariable cox regression for the effect of high-ACR, with HbA1c, blood pressure (BP), LDL-cholesterol and BMI as covariates; diabetes duration was the time dependent variable. Results At baseline mean(SD) age was 14.3(1.6) years and diabetes duration 7.2(3.3) years. After a median 3.2 years, 83/710 (12%) had developed 3DR. In multivariable analysis, high-ACR (HR 2.03 95%CI: 1.29-3.20, p =0.002), higher mean HbA1c (1.34, 1.14-1.58, p=0.01) and higher baseline DBP SDS (1.43, 1.08-1.89, p=0.01) were independently associated with 3DR risk. Conclusions/interpretation High-ACR is associated with greater risk of 3DR in adolescents providing a target for future intervention studies.
National Health and Medical Research Council of Australia (NHMRC) 632521, Juvenile Diabetes Foundation International, British Heart Foundation, Diabetes UK, Canadian Clinical Trial Network.
Embargo Lift Date
This record's DOI: https://doi.org/10.17863/CAM.78690
This record's URL: https://www.repository.cam.ac.uk/handle/1810/331245
All Rights Reserved
Licence URL: http://www.rioxx.net/licenses/all-rights-reserved